National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Nivolumab (Opdivo®) for adjuvant treatment of oesophageal or gastro-oesophageal junction cancer. HTA ID: 21043

Nivolumab as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.

 

NCPE Assessment Process Ongoing
Rapid review commissioned 21/09/2021
Rapid review completed 20/10/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 28/10/2021
Pre-submission consultation with Applicant 20/12/2021
Full submission received from Applicant 11/05/2022
Current Status Full submission received from Applicant